Recently, DDX5 was found to participate in tumorigenesis and development by promoting cell proliferation, metastasis (Wang et al., 2013), reorganization of cytoskeleton (Wang D. et al., 2012), and epithelial-mesenchymal transition (EMT) (Yang et al., 2006) of various cancers, such as breast cancer (Guturi et al., 2014), prostate cancer (Clark et al., 2008), colorectal cancer (Dai et al., 2018), glioma (Wang R. et al., 2012), and leukemia (Mazurek et al., 2014). This evidence concerns the gene DDX5 and central nervous system cancer.